<DOC>
	<DOCNO>NCT02281266</DOCNO>
	<brief_summary>Efficacy safety Thymalfasin adjuvant therapy HBV-related HCC curative resection .</brief_summary>
	<brief_title>Thymalfasin Adjuvant Therapy Hepatitis B Virus ( HBV ) -Related Hepatocellular Carcinoma ( HCC ) After Curative Resection</brief_title>
	<detailed_description>Multi-center , Randomized , Controlled Clinical Trial Evaluate Efficacy Safety Adjuvant Thymalfasin Therapy Hepatitis B Virus ( HBV ) -Related Hepatocellular Carcinoma After Curative Resection .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>Inclusion criterion perioperative period Male female patient age 1870 year . Life expectance ≥ 3 month . Diagnosis Hepatocellular Carcinoma confirm Histological Cytological examination . Hepatitis B history current HBsAg positive and/or HBV DNA positive Will undergo hepatic curative resection . Tumor feature a. cancer embolus b. solitary nodule measure 38 cm 2 nodule , total combine measurement 38 cm East Cooperative Oncology Group performance score 02 Normal liver function sufficient liver function , define Chlid'sPugh A Inclusion criterion baseline postoperation ( 4weeks ± 7days postoperation ) No document evidence disease recurrence compute tomography ( CT ) scan CT angiography . Grade A Chlid'sPugh score hematological test white blood cell ( WBC ) &gt; 3.5X109/L , red blood cell ( RBC ) &gt; 30 % , platelet count ( PLT ) &gt; 50,000/Ul , neutrophil ( NEU ) &gt; 1.0X109/L , Cr &lt; 1.5 mg/dl sign informed consent Any anticancer therapy , include liver transplant , transarterial Chemoembolization ( TACE ) , imageguided tumor ablation , radiotherapy , chemotherapy , molecular target therapy immunotherapy , etc . prior liver surgery procedure . Taking hepatotoxic drug immunosuppressant drug . Invasion portal vascular first branch , hepatic duct first branch , inferior vena cava hepatic vein . Organ transplant recipient . Extrahepatic organ lymph node metastasis . Uncontrolled Hypertension , unstable angina within 3 month , congestive heart failure ( New York Heart Association ( NYHA ) Class II great ) , history myocardial infarction within 6 month prior randomization severe arrhythmia need treat . History malignancy successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma and/or localize carcinoma situ cervix Known human immune deficiency virus ( HIV ) infection hepatitis C virus ( HCV ) infection History stroke transient ischemic attack within 6 month prior randomization Active untreated central nervous system ( CNS ) metastasis History clinically significant drug alcohol abuse Prior treatment immunomodulator ( e.g . interferon , Thymalfasin ) traditional Chinese medicine within 30 day prior randomization Know postoperative complication ( e.g . infection , bleeding , bile leak ) baseline Known allergic reaction investigational product excipient . Female subject pregnant breastfeed consider become pregnant study . The investigator considers subject , reason , unacceptable study participation . Participating clinical trial drug medical device within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>